Brief: Agenus Data At CTOS 2022 Highlight Durable Clinical Responses Of Botensilimab / Balstilimab Combination In Advanced Sarcoma

Agenus

17/11/2022 13:56

Nov 17 (Reuters) - Agenus Inc  AGEN.O :
    * AGENUS DATA AT CTOS 2022 HIGHLIGHT DURABLE CLINICAL
RESPONSES OF
BOTENSILIMAB / BALSTILIMAB COMBINATION IN ADVANCED SARCOMA
    * AGENUS-OVERALL RESPONSE RATE OF 46% & DISEASE CONTROL RATE
OF
69% IN HEAVILY PRE-TREATED PATIENTS WHO RECEIVED A MEDIAN OF 3
PRIOR LINES OF THERAPY
    * AGENUS INC - 67% OF PATIENT RESPONSES HAVE EXCEEDED ONE
YEAR AND
REMAIN ONGOING AT DATA CUT-OFF
    * AGENUS INC - PHASE 2 TRIAL OF BOTENSILIMAB/BALSTILIMAB IN
SARCOMAS PLANNED FOR 2023

Source text for Eikon:  ID:nGNX9fzp6v 
Further company coverage:  AGEN.O